基特突变和表达:当前的知识和新的见解,以克服IM在GIST的阻力
Shishan Zhou1, Omar Abdihamid2, Fengbo Tan3
1Division of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China, Xiangya road 87.
Cell communication and signaling : CCS
|February 28, 2024
概括
胃肠道 stromal 瘤 (GIST) 由于二次 KIT 突变,往往会对伊马替尼治疗产生耐药性. 了解GIST中的KIT基因调节,为克服意马替尼抗性提供了新的治疗点.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 胃肠层瘤 (GIST) 是最常见的胃肠肉瘤,起源于卡哈尔 (ICC) 的间歇细胞,并严重依赖KIT信号通路.
- 在未接受过治疗的GIST患者中,KIT突变存在于80-90%的患者中,伊马替尼 (IM) 是主要的向治疗.
- 治疗耐药性,通常是由于二次KIT突变,在大多数患者中发生,突出显示了对替代治疗策略的需求.
研究的目的:
- 阐明GIST中KIT变体的生物机制.
- 在GIST中更新对KIT基因表达调节的理解.
- 确定潜在的治疗点,以克服意马替尼布耐药性.
主要方法:
- 关于GIST中KIT突变,表达和调节的现有文献的审查.
- 对影响KIT表达的遗传和表观遗传因素的分析.
- 探索KIT突变体的蛋白质前和后翻译修饰.
主要成果:
- 在未接受过治疗的GIST患者中,80-90%存在KIT突变.
- 二次KIT突变是对~90%的伊马替尼布耐药性的原因.
- 在GIST中高KIT表达与基因放大无关,但与野生类型KIT相比,涉及不同的遗传和表观遗传调节.
结论:
- 了解GIST中KIT表达的独特调节,是开发抗伊马替尼抗药性策略的关键.
- 针对KIT变体的特定生物机制提供了一个有前途的治疗场景.
- 对基因编码,表观遗传学调节和蛋白质翻译进行进一步的研究是有效的GIST治疗的必要条件.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


